EE53 Cost-Minimization and Budget Impact Analysis of Venetoclax Versus Acalabrutinib for 1L and R/R Chronic Lymphocytic Leukemia in the Brazilian Public Healthcare System
Abstract
Authors
E.R. Mattos W. Follador L. Campos R.C. Antunes C. Biella